middle.news
How AdAlta’s CAR-T Collaboration Could Transform Solid Cancer Treatment
8:54am on Friday 20th of February, 2026 AEDT
•
Biotechnology
Read Story
How AdAlta’s CAR-T Collaboration Could Transform Solid Cancer Treatment
8:54am on Friday 20th of February, 2026 AEDT
Key Points
Half-year loss narrowed slightly to $2.44 million
Entered collaboration with Shanghai Cell Therapy Group for CAR-T therapy BZDS1901
Raised $2.8 million in placements during the period
Reduced operating costs by 31% through cost management
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Adalta (ASX:1AD)
OPEN ARTICLE